



WHAT IS
REFERENCE
PRICING?


Reference prices apply
if the G-BA concludes its
early benefit assessment
with **"No additional
benefit (proven)"...**



... and the
product falls into
a reference price
group.



Then, the reference
price dictates the
maximum price
that SHI funds will
pay for the drug.



Reference pricing in Germany




**Gemeinsamer
Bundesausschuss**

→
**Early benefit
assessment**

**No additional
benefit (proven)**



**Reference price group
exists**



**Reference price = maximum
reimbursed price**

If the drug cannot be assigned to a reference price group, the reimbursement price will be negotiated.



The negotiated price
will be set so that the
annual therapy costs are
not higher than those
for the appropriate
comparator therapy



Reference pricing in Germany




**Gemeinsamer
Bundesausschuss**

→
**Early benefit
assessment**

**No additional
benefit (proven)**



**Reference price group
exists**



**Reference price = maximum
reimbursed price**



**Reference price group
does not exist**



**Negotiated price = maximum
annual costs of ACT**

Want to find out more?

Get In Touch



anja@anjapownell.com



germanmarketaccesssimplified.com

or get my **Free Guide to German HTA system**

A detailed guide to the 10 most commonly asked questions regarding early benefit assessments

